CN113939302A - 医药组合物 - Google Patents

医药组合物 Download PDF

Info

Publication number
CN113939302A
CN113939302A CN202080042617.3A CN202080042617A CN113939302A CN 113939302 A CN113939302 A CN 113939302A CN 202080042617 A CN202080042617 A CN 202080042617A CN 113939302 A CN113939302 A CN 113939302A
Authority
CN
China
Prior art keywords
cells
pharmaceutical composition
cancer
cell
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042617.3A
Other languages
English (en)
Chinese (zh)
Inventor
安井裕
等泰道
上野博之
金子新
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thyas Co ltd
Kyoto University NUC
Original Assignee
Thyas Co ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thyas Co ltd, Kyoto University NUC filed Critical Thyas Co ltd
Publication of CN113939302A publication Critical patent/CN113939302A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080042617.3A 2019-06-14 2020-06-12 医药组合物 Pending CN113939302A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019111293 2019-06-14
JP2019-111293 2019-06-14
PCT/JP2020/023308 WO2020251046A1 (ja) 2019-06-14 2020-06-12 医薬組成物

Publications (1)

Publication Number Publication Date
CN113939302A true CN113939302A (zh) 2022-01-14

Family

ID=73781238

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042617.3A Pending CN113939302A (zh) 2019-06-14 2020-06-12 医药组合物

Country Status (5)

Country Link
US (1) US20220233665A1 (https=)
EP (1) EP3984549A4 (https=)
JP (1) JPWO2020251046A1 (https=)
CN (1) CN113939302A (https=)
WO (1) WO2020251046A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023064787A (ja) * 2021-10-27 2023-05-12 国立大学法人京都大学 Ｔ細胞の品質評価方法、および当該方法に用いる試薬

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011225538A (ja) * 2010-03-31 2011-11-10 Toyama Prefecture がん免疫抑制解除剤、がん免疫治療用組成物及びがん免疫治療方法
US20140099254A1 (en) * 2012-08-14 2014-04-10 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN107075484A (zh) * 2014-07-18 2017-08-18 国立大学法人京都大学 从多能性干细胞诱导细胞免疫治疗用t细胞的方法
US20170267972A1 (en) * 2014-07-18 2017-09-21 Hiroshi Kawamoto Production method for pluripotent stem cells having antigen-specific t cell receptor gene
US20170360911A1 (en) * 2014-12-09 2017-12-21 Sapporo Medical University Tumor antigen peptide
WO2017221975A1 (ja) * 2016-06-23 2017-12-28 国立大学法人京都大学 Ｃｄ４ｃｄ８両陽性ｔ細胞の製造方法
AU2016305550A1 (en) * 2015-08-07 2018-03-29 Cell Therapy Limited Immuno-oncology mesodermal progenitor (ioMP) cell
CN108697737A (zh) * 2015-11-05 2018-10-23 格雷克斯迪姆医疗私人有限公司 在免疫疗法中使用的组合物
WO2019070021A1 (ja) * 2017-10-06 2019-04-11 サイアス株式会社 ｉＰＳ細胞由来の遺伝的多様性を有するＴ細胞集団の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011096482A1 (ja) * 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
TW201835100A (zh) * 2017-02-06 2018-10-01 國立研究開發法人國立癌症研究中心 新穎ｔ細胞受體
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011225538A (ja) * 2010-03-31 2011-11-10 Toyama Prefecture がん免疫抑制解除剤、がん免疫治療用組成物及びがん免疫治療方法
US20140099254A1 (en) * 2012-08-14 2014-04-10 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN107075484A (zh) * 2014-07-18 2017-08-18 国立大学法人京都大学 从多能性干细胞诱导细胞免疫治疗用t细胞的方法
US20170267972A1 (en) * 2014-07-18 2017-09-21 Hiroshi Kawamoto Production method for pluripotent stem cells having antigen-specific t cell receptor gene
US20170360911A1 (en) * 2014-12-09 2017-12-21 Sapporo Medical University Tumor antigen peptide
AU2016305550A1 (en) * 2015-08-07 2018-03-29 Cell Therapy Limited Immuno-oncology mesodermal progenitor (ioMP) cell
CN108697737A (zh) * 2015-11-05 2018-10-23 格雷克斯迪姆医疗私人有限公司 在免疫疗法中使用的组合物
WO2017221975A1 (ja) * 2016-06-23 2017-12-28 国立大学法人京都大学 Ｃｄ４ｃｄ８両陽性ｔ細胞の製造方法
CN109415699A (zh) * 2016-06-23 2019-03-01 国立大学法人京都大学 Cd4cd8双阳性t细胞的制备方法
WO2019070021A1 (ja) * 2017-10-06 2019-04-11 サイアス株式会社 ｉＰＳ細胞由来の遺伝的多様性を有するＴ細胞集団の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAUL VIZCARDO等: "Regeneration of Human Tumor Antigen-Specific T Cells from iPSCs Derived from Mature CD8+ T Cells", 《CELL STEM CELL》, vol. 12, no. 1, 3 January 2013 (2013-01-03), pages 31 - 33, XP055240588, DOI: 10.1016/j.stem.2012.12.006 *

Also Published As

Publication number Publication date
US20220233665A1 (en) 2022-07-28
JPWO2020251046A1 (https=) 2020-12-17
EP3984549A4 (en) 2023-08-02
EP3984549A1 (en) 2022-04-20
WO2020251046A1 (ja) 2020-12-17

Similar Documents

Publication Publication Date Title
US20240294871A1 (en) METHOD FOR PRODUCING CD8alpha+beta+ CYTOTOXIC T CELLS
US11578310B2 (en) Method for producing CD4/CD8 double-positive T cells
CN112513255A (zh) 介由iPS细胞制造再生T细胞群体的方法
CN113195710A (zh) T细胞或nk细胞的制造方法、t细胞或nk细胞的培养用培养基、t细胞或nk细胞的培养方法、维持未分化t细胞的未分化状态的方法和t细胞或nk细胞的增殖促进剂
WO2016010155A1 (ja) 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
EP4273234A1 (en) Method for producing regenerated t cell via ips cell
EP3693456A1 (en) Production method for ips cell-derived genetically diverse t cell colony
WO2015099134A1 (ja) 再構成されたｔ細胞レセプター遺伝子を有する多能性幹細胞由来のｔ前駆細胞を用いる免疫細胞療法
WO2022059780A1 (ja) ｉＰＳ細胞を介する再生Ｔ細胞の製造方法
WO2016010153A1 (ja) 免疫細胞療法用ｔ細胞の誘導方法
US20250177524A1 (en) Cell bank composed of ips cells for introducing t cell receptor gene
CN113939302A (zh) 医药组合物
CN116744947A (zh) 一种通过iPS细胞生产再生T细胞的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination